Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis

British Journal of Psychiatry

Volumn 194, Issue 5, 2009, Pages 439-445

  Cuesta, Manuel J ^a   De Jalon, Elena Garcfa ^a   Campos, M Soledadand ^a   Peralta, Victor ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BIPERIDEN; OLANZAPINE; RISPERIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GLOBAL COGNITIVE SCORE; HUMAN; INTELLIGENCE QUOTIENT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; ADOLESCENT; DRUG EFFECT; EDUCATIONAL STATUS; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOSIS; STATISTICS; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION; EDUCATIONAL STATUS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649394307     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.108.055137     Document Type: Article

References (47)

1. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998; 12: 426-45.
2. saykin AJ, Gur rc, Gur RE, Mozley PD, Mozley lh, Resnick SM, et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 1991; 48: 618-24.
3. cuesta MJ, Peralta V, Caro F, de Leon J. Schizophrenic syndrome and Wisconsin Card Sorting Test dimensions. Psychiatry Res 1995; 58: 45-51.
4. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 2001; 58: 24-32.
5. Kraus MS, Keefe RSE. Cognition as an outcome measure in schizophrenia. Br J Psychiatry 2007; 191 (suppl 50): S46-51.
6. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-30.
7. Green MF. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions. Am J Psychiatry 2007; 164: 992-4.
8. Cuesta MJ, Peralta V, Zarzuela A. Illness duration and neuropsychological impairments in schizophrenia. Schizophr Res 1998; 33: 141-50.
9. Heaton RK, Crowley TJ. Effects of psychiatry disorders and their somatic treatments on neuropsychological test results. In Handbook of Clinical Neuropsychology (eds SB Filskov, TJ Boll): 481-525. Wiley, 1981.
10. Medalia A, Gold J, Merriam A. The effect of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol. 1988; 3: 249-71.
11. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive fuctions in schizophrenia. J Abnorm Psychol 1989; 98: 367-80.
12. Cassens G, Inglis ak, Appelbaum PS, Gutheil TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990; 16: 477-99.
13. King DJ. The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry 1990; 157: 799-811.
14. Weickert TW, Goldberg TE. First- and second-generation antipsychotic medication and cognitive processing in schizophrenia. Curr Psychiatry Rep 2005; 7: 304-10.
15. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 2004; 55: 1013-22.
16. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 2007; 89: 211-24.
17. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007; 64: 633-47.
18. Sharma T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br 1 Psychiatry 1999; 174 (suppl 38): S44-51.
19. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007; 64: 1115-22.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR). APA, 2000.
21. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992; 49: 615-23.
22. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663-67.
23. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-97.
24. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Neuropsychology Press, 1985.
25. Wechsler DA. Standarized memory scale for clinical use. J Psychology 1945; 19: 87-95.
26. Spaulding W, Garbin CP, Dras SR. Cognitive abnormalities in schizophrenic patients and schizotypal college students. J Nerv Ment Dis 1989; 177: 717-28.
27. Penn DL, Van Der Does W, Spaulding W, Garbin CP, Linszen D, et al. Information processing and social cognitive problem solving in schizophrenia. J Nerv Ment Dis 1993; 181:13-20.
28. Hair JF, Black B, Babin B, Anderson RE, Tatham RL. Multivariate Data Analysis (6th edn). Pearson Prentice Hall, 2005.
29. Brown L, Sherbenou RJ, Johnsen SK. TONI-2 Test de Inteligencia No Verbal. TEA Ediciones, 1995.
30. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59: 12-9.
31. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994; 51: 124-31.
32. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000; 157: 549-59.
33. Lee SM, Chou yh, Li MH, Wan FJ, Yen mh. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1101-7.
34. Townsend LA, Norman RM. Course of cognitive functioning in first episode schizophrenia spectrum disorders. Expert Rev Neurother 2004; 4: 61-8.
35. Mohamed s, Paulsen JS, O'Leary D, Arndt S, Andreasen N. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch Gen Psychiatry 1999; 56: 749-54.
36. Riley EM, McGovern D, Mockler D, Doku VC, OCeallaigh S, Fannon DG, et al. Neuropsychological functioning in first-episode psychosis - evidence of specific deficits. Schizophr Res 2000; 43: 47-55.
37. Goldstein G, Shemansky WJ. influences on cognitive heterogeneity in schizophrenia. Schizophr Res 1995; 18: 59-69.
38. Gonzalez-Blanch C, Alvarez-Jimenez M, Rodriguez-Sanchez JM, Perez-lglesias R, Vazquez-Barquero JL, Crespo-Facorro B. Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders: timing and patterns. Eur Arch Psychiatry din Neurosci 2006; 256: 364-71.
39. Peralta V, Cuesta MJ. A dimensional and categorical architecture for the classification of psychotic disorders. World Psychiatry 2007; 6: 36-7.
40. Reichenberg A, Weiser M, Rapp MA, Rabinowitz J, caspi A, Schmeidler J, etal. Pre-morbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based study. Schizophr Res 2006; 85: 49-57.
41. Cannon M, Caspi A, Moffit TE, Harrington H, Taylor A, Murray RM, et al. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry 2002; 59: 449-56.
42. Heaton RK, Temkin N, Dikmen S, Avitable N, Taylor MJ, Marcotte TD, et al. Detecting change: a comparison of three neuropsychological methods, using normal and clinical samples. Arch din Neuropsychol 2001; 16: 75-91.
43. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164: 1061-71.
44. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study, schizophr Res 2001; 48: 17-28.
45. Lezak MD. Neuropsychological Assessment (3rd edn). Oxford University Press, 1995.
46. Vickers AJ. How many repeated measures in repeated measures designs? Statistical issues for comparative trials. BMC Med Res Methodol 2003; 3: 22.
47. Allison DB, Allison RL, Faith MS, Paultre F, Pi-Sunyer fx. Power and money: designing statistically powerful studies while minimizing financial costs. Psychol Methods 1997; 2: 20-33.